Bleeding

Dual antithrombotic therapy conferred less bleeding but similar rates of mortality, stroke, nonfatal MI and stent thrombosis compared with triple antithrombotic therapy in patients with atrial fibrillation and concomitant CAD, according to a meta-analysis published in The American Journal of Cardiology.

SAN FRANCISCO — Among patients who had PCI with a drug-eluting stent and were on dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy lowered bleeding risk without raising ischemic risk compared with continued DAPT, according to results of the TWILIGHT trial presented at TCT 2019.

Patients aged at least 80 years who underwent PCI had an increased risk for in-hospital mortality and morbidity compared with those younger than 80 years, according to a study published in The American Journal of Cardiology.

Extended treatment with oral edoxaban appeared comparable to subcutaneous dalteparin in safety and effectiveness for prevention of recurrent venous thromboembolism and major bleeding among patients with active cancer, according to results of a post-hoc analysis published in Journal of Thrombosis and Haemostasis.

Continuous-flow ventricular assist devices have become a life-sustaining treatment option for patients with advanced HF during the past decade.